Limit search to available items
Record 74 of 83
Previous Record Next Record
E-book
Author Feddersen, Timothy James, 1958-

Title Roche and Tamiflu : doing business in the shadow of pandemic / Timothy Feddersen
Published [Evanston, IL] : Kellogg School of Management, ©2007

Copies

Description 1 online resource (22 pages) : color maps, charts
Series Human resource management online (text)
Summary The spread of bird flu outside of Asia, particularly in Africa and Europe, topped headlines in 2006. The migration of wild birds brought the virus to Europe, where for the first time it spread to productive livestock, bringing it closer to the Western world. Due to today's globalized and highly interconnected world, the consequences of a potential bird flu pandemic are expected to be much more severe than those of the Spanish flu, which killed 50-100 million people between 1918 and 1921. As of July 2006, 232 cases of human infection had been documented, mostly through direct contact with poultry. Of those, 134 people died. The best medication available to treat bird flu was Roche's antiviral drug Tamiflu. However, Tamiflu was not widely available; current orders of government bodies would not be fulfilled until the end of 2008. Well aware that today's avian flu might become a global pandemic comparable to the Spanish flu, Roche CEO Franz Humer had to decide how Roche should respond. While the pharmaceutical industry continued its research efforts on vaccines and medications, Tamiflu could play an important role by protecting healthcare workers and helping to contain the virus--or at least slow down its spread. Due to patent protection and a complicated production process with scarce raw ingredients, Roche had been the only producer of the drug. Partly in response to U.S. political pressure, in November 2005 Roche allowed Gilead to produce Tamiflu as well. Even so, it would take at least until late 2007 for Roche and Gilead to meet the orders of governments worldwide. The issue was a difficult one for Roche: What were the risks; what were the opportunities?
Notes Title from resource description page (viewed Aug. 7, 2014)
HBS number: KEL349
Case number: 5-107-010
Bibliography Includes bibliographical references
Notes This edition in English
Subject Crisis management -- Case studies
Pharmaceutical policy -- United States -- Case studies
Crisis management
Pharmaceutical policy
United States
Genre/Form Case studies
Case studies.
Études de cas.
Form Electronic book
Author Kellogg School of Management.